SAMPLE PREP 2015 - 樣品製備技術學會 2015 -
2015年6月25 - 26日
美國,馬里蘭州,貝塞斯達

分析前/檢測前處理的優化,應該緊密跟隨或甚至優先於新體學分析的興起。創新樣品製備與標的濃縮技術對於異體樣品或是包含低濃度檢體的樣品來說,具有大幅提升檢驗的敏感性與特異性的能力。適當且新式的樣品製備,對於確保重複性與強健性的分析平台與確效來說,為極為重要的一個部分。本會議將針對在臨床、生物檢測以及生物監測領域,因應最新體學分析的樣品製備相關主要課題與最新進展進行交流討論。


第1天 | 第2天

6月25日(四)

7:15 報到登記與晨間咖啡


基因檢測與病原體檢測之分析前處理最佳實務

8:10 議長開會致詞

8:15 生物檢體的生物質量評價

Scott-JewellScott D. Jewell, Ph.D., Professor and Director, Program for Technologies and Cores Van Andel Research Institute

Biospecimen quality is affected by preanalytical variable and the analytes from the biospecimen are the targets of that quality assessment. Purity, size, integrity and a functional assessment of nucleic acids are used to measure genomic biospecimen quality. However, a more complex measurement of quality is the assessment of the biology of the biospecimen. We investigate these questions using animal models to provide further improvements in best practices.

8:45 共同簡報:做為創新且高度整合的分子系統核心特徵的樣品製備

Randy-RasmussenRandy Rasmussen, Ph.D., President and COO, BioFire Diagnostics

Stephanie Thatcher, Ph.D., Director, Systems Integration, BioFire Diagnostics

Development of molecular detection systems focuses on nucleic acid amplification and detection. This half of the problem gets the grants, the patents and the research time. Unfortunately these systems are often brought to their knees by snot, blood, poop and sputum. The hardest part of highly integrated systems is the sample prep and yet it is the part that is hardest to get people to work on. We will describe the process of learning this lesson with the FilmArray system, how we approach sample prep, and what important factors you should consider during development.

9:30 直接全血檢體的細菌感染及念珠菌感染的敏感分子檢測

Lawrence-BlynLawrence B. Blyn, Ph.D., Director, Science and Technology, Ibis Biosciences, Abbott

We describe a sample preparation and detection system that provides for the rapid detection and identification of bacterial and Candidal nucleic acid directly in whole blood specimens from patients with suspected bloodstream infections. A lysis method and DNA purification system were designed for processing 5 ml of whole blood. PCR amplification formulations were optimized for high levels of human DNA. The system provides for rapid and sensitive molecular detection of diverse agents of these clinically important infections in approximately 6h.

10:00 展示會場休息與論文海報鑑賞

10:45 使用次世代定序分析以比較從合適福馬林固定組織及冰凍組織檢體所獲得的結果

Patrick-HurbanPatrick Hurban, Ph.D., Vice President, Research and Development, Expression Analysis, The Quintiles Company

Formalin-fixed tissues present many sample preparation, extraction and method development challenges. It can also be challenging to understand whether certain findings stem from intrinsic genetic properties of the sample, or alternatively, are a product of how the sample was handled. Despite advancements in preservation methods, vast collections of FFPE material await analysis. Results will be presented comparing matched formalin-fixed and frozen tumor samples analyzed using a sensitive next-generation sequencing assay.

11:15 標靶RNA定序的融合檢測最佳實務:分析前考量事項、分析確效等

Robert-DaberRobert D. Daber, Ph.D., Director, Research and Development and Sequencing Operations, Bio-Reference Laboratories

This presentation will discuss challenges and benefits of NGS based targeted RNA sequencing in the detection of gene fusion events, including, nucleic acid isolation, sample preparation and downstream data processing. There are a number of specific challenges related to RNA sequencing, standardized quality control metrics both before and after library prep are clearly needed.

11:45 贊助商簡報發表

12:15 午餐會簡報發表或是自行享用午餐

1:00 展示會場休息與論文海報鑑賞

1:40 議長致詞

1:45 癌症臨床研究使用的多重檢體NGS分析的準備

Mickey-WilliamsP. Mickey Williams, Ph.D., Director, Molecular Characterization & Clinical Assay Development Laboratory (MoCha), Frederick National Laboratory for Cancer Research

NGS offers a powerful tool for assessment of molecular defects found in cancer. The utilization of NGS is becoming common practice in clinical laboratories. This complex technology requires a new level of analytical performance testing and validation. This discussion will focus on approaches used for analytical validation of the NGS clinical assay used for treatment selection in the NCI-MPACT Study.

2:15 部分臨床樣品的多重標的定序

Curt-ScharfeCurt Scharfe, M.D., Ph.D., Senior Scientist, Stanford Genome Technology Center, Stanford University

Clinical molecular testing increasingly depends on the development and deployment of novel sample preparation technologies. In collaboration with physicians and clinical laboratories we are developing genomic and sequencing assays for the screening and diagnosis of cystic fibrosis, clinical viral infections, newborn and neurodevelopmental conditions and inherited cardiomyopathies. These projects have involved invention of a novel multiplex capture technology, and several innovative improvements in DNA sample preparation. Both approaches have increased speed and accuracy, while lowering costs.

2:45 展示會場休息與論文海報鑑賞

3:15 透過DeepChek&OncoChek平台的病毒學及腫瘤學的樣品製備與分析確效的優化

Chalom-SayadaChalom Sayada, M.D., Ph.D., Co-founder & CEO, Advanced Biological Laboratories SA

Clinical environments wishing to provide genotyping services in the field of Virology or Human Genetics using Next Generation Sequencing (NGS) need robust, standardized, registered and well-validated software systems. These should be tailored to the optimized management of genomic data resulting in personalized healthcare. Dedicated downstream analysis systems help to perform an accurate, quick and simple analysis of NGS data. This begins with sample preparation and the generation of reads by any type of sequencing platform and ends with simple and easily-understandable reporting ideally suited to clinical interpretation and the connection to the local LIMS. Coupling advanced IT solutions to a well-established sequencing workflow usually helps labs with the validation of new sample prep and innovative assays, enhancing patient management.

3:45 贊助商簡報發表


4:15 座談會:核酸萃取法與分析目標的配合

Moderator:
Patrick-HurbanPatrick Hurban, Ph.D., Vice President, Research and Development, Expression Analysis, The Quintiles Company





Panelists: Speakers of the Day


4:45 專題研討會報到登記

5:30-8:30 晚餐專題研討會(需要另外報名登記。)



第1天 | 第2天

6月26日(五)

8:00 晨間咖啡


多重分析:樣品製備與確效

8:25 議長致詞

8:30 切合目的的生物檢體採樣與使用規範的National Cancer Institute資源

Helen-MooreHelen Moore, Ph.D., Branch Chief, Biorepositories & Biospecimen Research Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

The National Cancer Institute has led the way in developing Best Practices for Biospecimen Resources, sponsoring new research in Biospecimen Science, and building groundbreaking research biospecimen collections including postmortem biospecimens for the NIH GTEx program. New projects to build evidence-based best practices for frozen and FFPE tissues will be described.

9:00 針對NGS成功的FFPE樣品評價

Helen-FernandesHelen Fernandes, Ph.D., Associate Professor, Pathology and Laboratory Medicine, Weill Cornell Medical College

This presentation will discuss several important issues, such as: RNA detection in cancer tissues stored in FFPE samples, profiling microRNA expression, FFPE DNA quality control and its correlation with NGS data, and understanding pre-analytic effects on RNA gene expression.

9:30 贊助商簡報發表

10:00 休息時間


因應各種適應症的分析前考量事項

10:15 從血液檢體直接採樣的活菌快速樣品製備

Alexis-Sauer-BudgeAlexis Sauer-Budge, Ph.D., Senior Research Scientist, Fraunhofer Center for Manufacturing Innovation; Adjunct Research Assistant Professor, Biomedical Engineering, Boston University

Traditionally, bacterial pathogens in the blodd have been identified using culture-based methods that can take several days to obtain results. This can lead to physicians making treatment decisions based on an incomplete diagnosis contributing to patient morbidity. To decrease diagnosis time, we are developing a novel sample preparation device for isolating and concentrating dilute bacteria from blood. This presentation will describe the sample preparation device for methodology to isolate viable bacteria from blood which is clean enough for direct PCR or other downstream detection technologies.

10:45 細菌隔離與可攜式檢測:分析前考量事項與技術

Sam-NugenSam R. Nugen, Ph.D., Assistant Professor, Department of Food Science, University of Massachusetts, Amherst

The lack of a practical method for bacterial separation remains a hindrance for the low-cost and successful development of rapid detection methods from complex samples. We have developed T7 bacteriophage magnetic probes, where T7 bacteriophage is bound to magnetic particles. The capture efficiencies of bacteriophages on microbeads and nanoparticles for the separation of E. coli K12 were determined. The results indicated that bacteriophage magnetic particles achieved a capture efficiency of 93.7 簣 1.1% in 15 minutes.

11:15 GAA次世代定序的微流體PCR擴增以檢測造成龐貝氏症的突變原因

Patricia Mueller, Ph.D., Chief, Molecular Risk Assessment Laboratory, Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention (CDC)

We designed a next-generation sequencing assay using primer pairs for PCR amplification and library preparation of up to 48 samples in one Fluidigm Access Array for next-generation sequencing using the MiSeq. This assay can be scaled up using additional Access Arrays in one MiSeq run. The PCR amplification of GAA is challenging due to difficult regions in the gene. All transcribed exon sequences as well as exon/intron borders including those intron sequences containing mutations as identified in the Human Genome Mutation Database (HGMD) were targeted for amplification. Primers were designed not to overlap known HGMD mutations, and variants found in dbSNP were avoided when possible. The data was filtered at a quality score of ??30 and trimmed. We characterized reference materials including those with missense, nonsense, and splicing mutations; and small insertions and deletions. Large deletions that included exon 18 were independently characterized.

11:45 分析前變數-生物標記確效上最脆弱且未受到充分評價的階段

Apurva K. Srivastava, Ph.D., Principal Scientist, Frederick National Laboratory for Cancer Research Leidos Biomedical Research, Inc.

Contrary to prevalent belief, pre-analytic factors contribute to the most errors documented in clinical laboratories as compared to analytical factors where most efforts are devoted during assay validation. Dr. Srivastava will discuss the general pre-analytical variables for protein assays and how they affect accuracy in clinical laboratory tests. The focus of his presentation will be on identifying the phases of pre-analytical factors with reference to pharmacodynamic/proof-of-mechanism (POM) phospho-protein biomarkers in clinical trials. As a take home message, participants will learn that pre-analytic variables are an underappreciated area in biomarker validation process and improvements in this process will significantly impact accuracy of test results and enable laboratories to focus their quality assurance efforts.

12:15 學會結束


第1天 | 第2天


* 活動內容有可能不事先告知作更動及調整。

 

Choose your language
Chinese
Japanese
Korean
English


Catalog


產業會議彙總曆
醫療設備相關國際會議

醫療設備相關國際會議

免費電子郵件通知服務
免費電子郵件通知服務